TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00074438
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral or parenteral repeating dose
Study: NCT00074438
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00074438
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT02713204
Drug: REGN910-3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02290327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of 0.9% normal saline
Study: NCT00810381
Drug: Physiologic saline solution (control substance)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion, infusion period 120 minutes
Study: NCT01138150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
Study: NCT02164773
Drug: 0.9%normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.
Study: NCT01424982
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01424982
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01424982
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01424982
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01040221
Drug: Trichuris Suis Ova
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.
Study: NCT00903383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo dosing with daily oral intake for 12 weeks
Study: NCT02950753
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid bolus or Normal Saline (30ml/kg).
Study: NCT03624270
Drug: Oral arsenic Trioxide, ATRA and ascorbic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral arsenic trioxide-based frontline induction, consolidation and maintenance will be provided to patients with newly diagnosed acute promyelocytic leukemia.
Study: NCT02854683
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 liter of intravenous saline will be delivered over 1 hour
Study: NCT00602667
Drug: Induction Chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive 4 identical cycles of induction chemotherapy including highdose (5 g/m2 or 2.5g/m2 for patients less than or equal to 31 days of age at enrollment) intravenous methotrexate and standard dose vincristine, cisplatin, and cyclophosphamide.
Study: NCT00602667
Drug: Intermediate-Risk Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction will be followed by consolidation focal radiotherapy (RT) to the tumor bed. Patients less than 12 months old upon completion of induction will receive low risk chemotherapy to delay RT until the age of 12 months. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).~Note: The option to receive focal proton beam irradiation was suspended 10/29/2015. Focal photon beam irradiation continues as part of the treatment plan.
Study: NCT03432286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SQ
Study: NCT00468923
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 10 mg once daily
Study: NCT01965652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken orally once a day
Study: NCT00776633
Drug: oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00140946
Drug: Comparator: placebo / Duration of Treatment: 16 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01488019
Drug: Perforomist-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vehicle, 2mL, twice daily for 52 weeks
Study: NCT01488019
Drug: Perforomist, nebulization, COPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perforomist, 20 mcg/2 mL, twice daily for 52 weeks
Study: NCT00756028
Drug: Patients receiving short protocol IVF/ICSI-treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day
Study: NCT00756028
Drug: Long protocol
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
Study: NCT04597762
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone eyedrops
Study: NCT01536678
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of 600mcg of test formulation of levothyroxine administered in dosing period 1 or 2.
Study: NCT01536678
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of 600mcg of reference formulation of levothyroxine administered in dosing period 1 or 2.
Study: NCT03550209
Drug: LCPUFA Oil Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
Study: NCT02362906
Drug: Xiyanping injection
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection
Study: NCT02362906
Drug: wind-heat formula granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
Study: NCT02362906
Drug: phlegm-heat formula granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
Study: NCT02362906
Drug: Fu-xiong San
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: external application; 8-10 cm wide, 0.3-0.5 cm thick;10 mins for patient aged 1 to 3-year old; 15 mins for those aged 3 to 5-year old; once daily
Study: NCT02362906
Drug: second generation cephalosporin
Normalized name: Second generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02362906
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ivd. 30 mg/(kg•d), plus 5% Glucose Injection, 80 to 500 ml, ivd. Once a day injection
Study: NCT02362906
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ivd. 10 mg/(kg•d), plus 5% Glucose Injection, 100 to 500 ml, ivd. Once a day injection
Study: NCT01357356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04049552
Drug: Rapamycin 8% Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: A compounded ointment containing 8% rapamycin
Study: NCT04049552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum ointment placebo
Study: NCT00548353
Drug: MK3207
Approvals — FDA: no, EMA: no, PMDA: no
Description: M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).
Study: NCT00548353
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).
Study: NCT02056730
Drug: calcium sensing receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).
Study: NCT02297906
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drug
Study: NCT01856192
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01856192
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03984448
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03984448
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00244517
Drug: TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
Study: NCT00851344
Drug: GSK835726 (10mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK835726 (10mg) tablet
Study: NCT00851344
Drug: GSK835726 (50mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK835726 (50mg) tablet
Study: NCT00851344
Drug: GSK835726 (100mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK835726 (100mg) tablet
Study: NCT04069078
Drug: Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive IV study solution which is hyoscine butylbromide 20 mg in 1 ml one minute after spinal anaesthesia
Study: NCT03709680
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase 1 only: Administered at 250 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
Study: NCT02477969
Drug: PEX168(100µg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEX168,100µg,Subcutaneous injection,once a week. continued for 52 weeks
Study: NCT02477969
Drug: PEX168(200µg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEX168,Subcutaneous injection,once a week. continued for 52 weeks
Study: NCT02477969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then followed by PEX168 100µg,qw sc. or 200µg qw sc.for 28 weeks.
Study: NCT01631812
Drug: SPM 962
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study: NCT02482207
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01907100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib matching placebo
Study: NCT02800902
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prophylaxis followed by placement of placebo gel
Study: NCT02800902
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral prophylaxis followed by placement of rosuvastatin gel
Study: NCT04407052
Drug: Double trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
Study: NCT04407052
Drug: HCG trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
Study: NCT03655210
Drug: HL151
Normalized name: Hydroxylapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL151(1Tab) once a day for 4 weeks of treatments
Study: NCT00805701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03954132
Drug: Spiolto® Respimat®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to Spiolto® Respimat® inhaler by their attending physician in an real-world setting.
Study: NCT03954132
Drug: Triple-Therapy (LAMA/LABA/ICS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to any triple therapy Long-acting muscarinic antagonist + Long-acting beta2 adrenoceptor agonist + Inhalative Corticosteroids (LAMA + LABA + ICS) by their attending physician in an real-world setting.
Study: NCT00376428
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00979628
Drug: sliding scale regular insulin (SSRI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: four-time daily in patients with T2DM admitted to general medicine and surgery wards.
Study: NCT00979628
Drug: Basal Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)
Study: NCT00979628
Drug: Basal Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
Study: NCT00309478
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600mg/m2
Study: NCT00309478
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 40mg/m2
Study: NCT00309478
Drug: Fluorouracil implant
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil 600mg/m2
Study: NCT02479828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03318900
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02764697
Drug: H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection twice weekly
Study: NCT03104374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT03104374
Drug: ABT-494
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06680505
Drug: YZJ-1139 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: YZJ-1139 10mg tablets
Study: NCT06680505
Drug: YZJ-1139 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: YZJ-1139 20mg tablets
Study: NCT06680505
Drug: YZJ-1139 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: YZJ-1139 40mg tablets
Study: NCT06680505
Drug: YZJ-1139 60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: YZJ-1139 60mg tablets
Study: NCT06680505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Match placebo tablets
Study: NCT01211847
Drug: Diazoxide Choline Controlled-Release Tablet
Normalized name: diazoxide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCCR 290 mg once a day for 126 days
Study: NCT02883192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01397201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching fluticasone propionate HFA MDI
Study: NCT02905253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching AC-084 capsules
Study: NCT02294084
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive a placebo (once a day) for 12 weeks.
Study: NCT03623451
Drug: Chinese Medicine Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese Medicine Formula, composed of American ginseng 10g, Poria cocos 15g, bighead atractylodes rhizome 20g, Astragalus mongholicus 30g, Crataegus pinnatifida Bunge 20g, Salvia miltiorrhiza Bge. 20g, Pericarpium Citri Reticulatae 10g will be decocted and packaged into vacuum packs by the pharmaceutical department of First Affiliated Hospital, Heilongjiang University of Chinese Medicine (140 mL/pack). Subjects will take 2 packages per day for three months.
Study: NCT01211847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching DCCR
Study: NCT01964131
Drug: D961H HPMC capsule 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2). Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg
Study: NCT03280537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
Study: NCT03263559
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given at 14.5mg/kg on Day -6 and Day -5, and at 50 mg/kg on Days +3 and +4.
Study: NCT00003782
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles
Study: NCT02739165
Drug: ART-123
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy
Study: NCT02739165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by intravenous drip infusion in addition to standard of care steroid therapy
Study: NCT00003782
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles
Study: NCT02002247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.
Study: NCT02528175
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 weeks concurrent with radiation therapy (institutional standard).
Study: NCT04467931
Drug: ACEI/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veterans will be categorized as exposed to ACEI/ARB if they have one or more pharmacy fills for an oral ACEI or an ARB in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
Study: NCT03705585
Drug: Vivotif Typhoid Oral Vaccine
Normalized name: Vivotif Typhoid Oral Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
Study: NCT04467931
Drug: Non-ACEI/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veterans will be categorized as exposed to a non-ACEI/ARB if they have one or more pharmacy fills for an oral non-ACEI or ARB medication in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an ACEI/ARB medication in the 90 days (± 14 days) prior to each Veteran's index date. Specific drug classes include: aldosterone receptor antagonist, beta-blocker, calcium channel blocker, centrally-acting drug, direct arterial vasodilator, direct renin inhibitor, thiazide diuretic, loop diuretic, and potassium sparing diuretic.
Study: NCT04467931
Drug: ACEI
Normalized name: Veneno de Abeja Aceite de Vibora
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veterans will be categorized as exposed to an ACEI if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ARB in the 90 days (± 14 days) prior to each Veteran's index date.
Study: NCT04467931
Drug: ARB
Normalized name: Arbli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veterans will be categorized as exposed to an ARB if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
Study: NCT00408538
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01238185
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01340547
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1